Trial · NCT01742208
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Total Daily Bolus Amount of Exogenous Insulin Required Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Sotagliflozin 400 mg - Pioneer Group | -46.32 | 95% Confidence Interval -99.71 to 7.06 | percent change | |
| Percent Change From Baseline in Total Daily Bolus Amount of Exogenous Insulin Required Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Placebo - Expansion Group | -7.00 | 95% Confidence Interval -19.18 to 5.17 | percent change | |
| Percent Change From Baseline in Total Daily Bolus Amount of Exogenous Insulin Required Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Sotagliflozin 400 mg - Expansion Group | -32.14 | 95% Confidence Interval -45.09 to -19.18 | percent change | |
| Percent Mean Change From Baseline in Daily Bolus Amount of Exogenous Insulin Required at Each Meal Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Sotagliflozin 400 mg - Pioneer Group | Before Breakfast | -42.19 | 95% Confidence Interval -169.85 to 85.46 | percent change |
| Percent Mean Change From Baseline in Daily Bolus Amount of Exogenous Insulin Required at Each Meal Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Placebo - Expansion Group | Before Breakfast | 10.79 | 95% Confidence Interval -13.28 to 34.86 | percent change |
| Percent Mean Change From Baseline in Daily Bolus Amount of Exogenous Insulin Required at Each Meal Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Sotagliflozin 400 mg - Expansion Group | Before Breakfast | -25.16 | 95% Confidence Interval -51.15 to 0.82 | percent change |
| Percent Mean Change From Baseline in Daily Bolus Amount of Exogenous Insulin Required at Each Meal Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Sotagliflozin 400 mg - Pioneer Group | Before Lunch | -59.02 | 95% Confidence Interval -109.11 to -8.93 | percent change |
| Percent Mean Change From Baseline in Daily Bolus Amount of Exogenous Insulin Required at Each Meal Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Placebo - Expansion Group | Before Lunch | 3.94 | 95% Confidence Interval -19.33 to 27.20 | percent change |
| Percent Mean Change From Baseline in Daily Bolus Amount of Exogenous Insulin Required at Each Meal Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Sotagliflozin 400 mg - Expansion Group | Before Lunch | -25.85 | 95% Confidence Interval -50.59 to -1.12 | percent change |
| Percent Mean Change From Baseline in Daily Bolus Amount of Exogenous Insulin Required at Each Meal Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Sotagliflozin 400 mg - Pioneer Group | Before Dinner | -34.83 | 95% Confidence Interval -129.08 to 59.42 | percent change |
| Percent Mean Change From Baseline in Daily Bolus Amount of Exogenous Insulin Required at Each Meal Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Placebo - Expansion Group | Before Dinner | 33.34 | 95% Confidence Interval -6.53 to 73.22 | percent change |
| Percent Mean Change From Baseline in Daily Bolus Amount of Exogenous Insulin Required at Each Meal Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Sotagliflozin 400 mg - Expansion Group | Before Dinner | -24.02 | 95% Confidence Interval -66.57 to 18.54 | percent change |
| Percent Change From Baseline in Total Daily Amount of Exogenous Insulin (Total Daily Bolus + Total Daily Basal) Required Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Sotagliflozin 400 mg - Pioneer Group | -27.00 | 95% Confidence Interval -40.65 to -13.35 | percent change | |
| Percent Change From Baseline in Total Daily Amount of Exogenous Insulin (Total Daily Bolus + Total Daily Basal) Required Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Placebo - Expansion Group | -1.20 | 95% Confidence Interval -10.03 to 7.63 | percent change | |
| Percent Change From Baseline in Total Daily Amount of Exogenous Insulin (Total Daily Bolus + Total Daily Basal) Required Calculated Over Days 3 to 27 (Treatment Outpatient Period) | Sotagliflozin 400 mg - Expansion Group | -15.52 | 95% Confidence Interval -24.93 to -6.12 | percent change | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Day 29 | Sotagliflozin 400 mg - Pioneer Group | -54.2 | 95% Confidence Interval -85.1 to -23.4 | milligram/deciliter (mg/dL) | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Day 29 | Placebo - Expansion Group | 10.0 | 95% Confidence Interval -9.4 to 29.3 | milligram/deciliter (mg/dL) | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Day 29 | Sotagliflozin 400 mg - Expansion Group | -12.5 | 95% Confidence Interval -36.8 to 11.8 | milligram/deciliter (mg/dL) | |
| Change From Day 1 in 3-hour Plasma Glucose AUC (AUC0-3 h) Following a Mixed Meal Tolerance Test (MMTT) at Day 29: Expansion Groups | Placebo - Expansion Group | -140.83 | 95% Confidence Interval -225.45 to -56.20 | mg*h/dL | |
| Change From Day 1 in 3-hour Plasma Glucose AUC (AUC0-3 h) Following a Mixed Meal Tolerance Test (MMTT) at Day 29: Expansion Groups | Sotagliflozin 400 mg - Expansion Group | -308.51 | 95% Confidence Interval -393.51 to -223.50 | mg*h/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01742208/results